Skip to Main content Skip to Navigation
Journal articles

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

Celeste Lebbé 1, 2, 3 Caroline Dutriaux 4 Thierry Lesimple 5 Willem Kruit 6 Joseph Kerger 7 Luc Thomas 8 Bernard Guillot 9 Filippo de Braud 10, 11 Claus Garbe 12 Jean-Jacques Grob 13 Carmen Loquai 14 Virginia Ferraresi 15 Caroline Robert 16, 17 Paul Vasey Robert Conry 18 Richard Isaacs 19 Enrique Espinosa 20 Armin Schueler 21 Giorgio Massimini 21 Brigitte Dréno 22, 23
Abstract : This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg; oral twice-daily) or DTIC (1000 mg/m2; intravenously) on Day 1 of each 21-day cycle. Patients progressing on DTIC could crossover to pimasertib. Primary endpoint: investigator-assessed progression-free survival (PFS); secondary endpoints: overall survival (OS), objective response rate (ORR), quality of life (QoL), and safety. Overall, 194 patients were randomized (pimasertib n = 130, DTIC n = 64), and 191 received treatment (pimasertib n = 130, DTIC n = 61). PFS was significantly improved with pimasertib versus DTIC (median 13 versus 7 weeks, respectively; hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.42–0.83; p = 0.0022). ORR was improved with pimasertib (odds ratio 2.24, 95% CI 1.00–4.98; p = 0.0453). OS was similar between treatments (median 9 versus 11 months, respectively; HR 0.89, 95% CI 0.61–1.30); 64% of patients receiving DTIC crossed over to pimasertib. Serious adverse events (AEs) were more frequent for pimasertib (57%) than DTIC (20%). The most common treatment-emergent AEs were diarrhea (82%) and blood creatine phosphokinase (CPK) increase (68%) for pimasertib, and nausea (41%) and fatigue (38%) for DTIC. Most frequent grade ≥3 AEs were CPK increase (34%) for pimasertib and neutropenia (15%) for DTIC. Mean QoL scores (baseline and last assessment) were similar between treatments. Pimasertib has activity in NRAS-mutated cutaneous melanoma and a safety profile consistent with known toxicities of MEK inhibitors. Trial registration: ClinicalTrials.gov, NCT01693068.
Complete list of metadata

https://hal.umontpellier.fr/hal-03256625
Contributor : Anthony Herrada <>
Submitted on : Thursday, June 10, 2021 - 12:58:50 PM
Last modification on : Tuesday, July 13, 2021 - 3:15:04 AM

File

cancers-12-01727-v2.pdf
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Celeste Lebbé, Caroline Dutriaux, Thierry Lesimple, Willem Kruit, Joseph Kerger, et al.. Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers, MDPI, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩. ⟨hal-03256625⟩

Share

Metrics

Record views

82

Files downloads

66